CU24263B1 - Derivados de imidazopiridazinas inhibidores de quinasa akt, útiles para el tratamiento del cáncer - Google Patents

Derivados de imidazopiridazinas inhibidores de quinasa akt, útiles para el tratamiento del cáncer

Info

Publication number
CU24263B1
CU24263B1 CUP2013000135A CU20130135A CU24263B1 CU 24263 B1 CU24263 B1 CU 24263B1 CU P2013000135 A CUP2013000135 A CU P2013000135A CU 20130135 A CU20130135 A CU 20130135A CU 24263 B1 CU24263 B1 CU 24263B1
Authority
CU
Cuba
Prior art keywords
cancer
useful
treatment
akt
inhibitors
Prior art date
Application number
CUP2013000135A
Other languages
English (en)
Other versions
CU20130135A7 (es
Inventor
Lars Bärfacker
Ulf Bömer
Hans Briem
Andrea Hägebarth
Stuart Ince
Roland Neuhaus
Oliver Politz
Hartmut Rehwinkel
William Johnston Scott
Original Assignee
Bayer Ip Gmbh
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ip Gmbh, Bayer Pharma AG filed Critical Bayer Ip Gmbh
Publication of CU20130135A7 publication Critical patent/CU20130135A7/es
Publication of CU24263B1 publication Critical patent/CU24263B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

<p>La invención se refiere a las imidazopiridazinas de fórmula (I)</p> <p>Espacio para Fórmula I</p> <p>que actúan en calidad de inhibidores de quinasa AKT y son útiles para el tratamiento del cáncer, y a un proceso para su preparación.</p>
CUP2013000135A 2011-04-07 2012-04-05 Derivados de imidazopiridazinas inhibidores de quinasa akt, útiles para el tratamiento del cáncer CU24263B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161472732P 2011-04-07 2011-04-07
PCT/EP2012/056300 WO2012136776A1 (en) 2011-04-07 2012-04-05 Imidazopyridazines as akt kinase inhibitors

Publications (2)

Publication Number Publication Date
CU20130135A7 CU20130135A7 (es) 2014-02-28
CU24263B1 true CU24263B1 (es) 2017-07-04

Family

ID=45953129

Family Applications (1)

Application Number Title Priority Date Filing Date
CUP2013000135A CU24263B1 (es) 2011-04-07 2012-04-05 Derivados de imidazopiridazinas inhibidores de quinasa akt, útiles para el tratamiento del cáncer

Country Status (43)

Country Link
US (2) US9206185B2 (es)
EP (1) EP2694510B1 (es)
JP (1) JP5906303B2 (es)
KR (1) KR20140022057A (es)
CN (1) CN103596957B (es)
AP (1) AP3597A (es)
AR (1) AR087148A1 (es)
AU (1) AU2012238589B2 (es)
BR (1) BR112013025777A2 (es)
CA (1) CA2832374A1 (es)
CL (1) CL2013002878A1 (es)
CO (1) CO6862145A2 (es)
CR (1) CR20130515A (es)
CU (1) CU24263B1 (es)
CY (1) CY1117163T1 (es)
DK (1) DK2694510T3 (es)
DO (1) DOP2013000226A (es)
EA (1) EA024890B1 (es)
EC (1) ECSP13013008A (es)
ES (1) ES2558780T3 (es)
GT (1) GT201300238A (es)
HR (1) HRP20160011T1 (es)
HU (1) HUE026323T2 (es)
IL (1) IL228567A0 (es)
JO (1) JO3068B1 (es)
MA (1) MA35016B1 (es)
ME (1) ME02316B (es)
MX (1) MX336865B (es)
NI (1) NI201300105A (es)
PE (1) PE20141380A1 (es)
PH (1) PH12013502073A1 (es)
PL (1) PL2694510T3 (es)
PT (1) PT2694510E (es)
RS (1) RS54480B1 (es)
SG (1) SG193631A1 (es)
SI (1) SI2694510T1 (es)
SM (1) SMT201600001B (es)
TN (1) TN2013000400A1 (es)
TW (1) TWI535719B (es)
UA (1) UA111739C2 (es)
UY (1) UY34006A (es)
WO (1) WO2012136776A1 (es)
ZA (1) ZA201307223B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9334242B2 (en) 2008-06-16 2016-05-10 Gtx, Inc. Compounds for treatment of cancer
LT2303021T (lt) 2008-06-16 2019-06-25 University Of Tennessee Research Foundation Junginiai, skirti vėžio gydymui
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
US9029408B2 (en) 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
US11084811B2 (en) 2010-03-01 2021-08-10 Oncternal Therapeutics, Inc. Compounds for treatment of cancer
SI2694510T1 (sl) * 2011-04-07 2016-02-29 Bayer Intellectual Property Gmbh Imidazopiridazini kot inhibitorji AKT kinaze
EP2802586B1 (en) * 2012-01-10 2016-05-25 Bayer Intellectual Property GmbH Substituted imidazopyrazines as akt kinase inhibitors
JP6106694B2 (ja) * 2012-01-10 2017-04-05 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ Ａｋｔキナーゼ阻害剤としての置換ピラゾロピリミジン類
SG11201503688SA (en) * 2012-11-30 2015-06-29 Glaxosmithkline Llc Novel pharmaceutical composition
CN109568312A (zh) 2013-03-05 2019-04-05 田纳西大学研究基金会 用于治疗癌症的化合物
US20150352121A1 (en) * 2013-03-12 2015-12-10 Glaxosmithkline Llc Combination
WO2014153001A1 (en) * 2013-03-14 2014-09-25 Epizyme, Inc. Combination therapy for treating cancer
CN105899512A (zh) * 2014-01-09 2016-08-24 拜耳医药股份公司 可用于治疗过度增殖性和/或血管生成疾病的酰胺基团取代的咪唑并哒嗪
US10774086B2 (en) 2016-11-28 2020-09-15 Bristol-Myers Squibb Company GSK-3 inhibitors
EP3453706A1 (en) 2017-09-08 2019-03-13 Basf Se Pesticidal imidazole compounds
GB2600384A (en) 2020-09-30 2022-05-04 Vaderis Therapeutics Ag Allosteric AKT inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2393724A1 (en) 1999-12-23 2001-06-28 Nitromed, Inc. Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use
AU2001249679A1 (en) 2000-03-31 2001-10-15 Ortho-Mcneil Pharmaceutical, Inc. Phenyl-substituted imidazopyridines
CN1308327C (zh) 2000-04-27 2007-04-04 安斯泰来制药有限公司 咪唑并吡啶衍生物
US7381825B2 (en) 2003-03-17 2008-06-03 Takeda San Diego, Inc. Histone deacetylase inhibitors
CN1809354A (zh) 2003-04-24 2006-07-26 麦克公司 Akt活性抑制剂
BRPI0412636A (pt) 2003-07-30 2006-09-26 S A L V A T Lab Sa imidazopirimidinas substituìdas para a prevenção e tratamento de cáncer
US7655649B2 (en) 2004-04-09 2010-02-02 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
AU2005290081B2 (en) 2004-08-23 2010-12-02 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
KR20070054216A (ko) 2004-08-24 2007-05-28 바스프 악티엔게젤샤프트 이온성 액체 제조의 출발 화합물로서의 용도를 위한이미다졸륨-메틸술파이트
WO2006065601A2 (en) 2004-12-15 2006-06-22 Merck & Co., Inc. Inhibitors of akt activity
MX2007014510A (es) 2005-05-20 2008-02-05 Array Biopharma Inc Compuestos inhibidores de raf y metodos de uso de los mismos.
HRP20130429T1 (en) 2005-06-10 2013-06-30 Merck Sharp & Dohme Corp. Inhibitors of akt activity
US20070049591A1 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Inhibitors of MAPK/Erk Kinase
PE20070978A1 (es) 2006-02-14 2007-11-15 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
US7530313B2 (en) 2006-05-12 2009-05-12 Day & Zimmerman, Inc. Self-destruct fuze delay mechanism
AR064010A1 (es) 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt
SG182187A1 (en) * 2007-06-08 2012-07-30 Abbott Gmbh & Co Kg 5-heteroaryl substituted indazoles as kinase inhibitors
PE20090944A1 (es) 2007-08-14 2009-08-09 Bayer Schering Pharma Ag PIRIMIDINAS BICICLICAS FUSIONADAS COMO INHIBIDORES DE LA VIA Pi3K/AKT
AU2008288390A1 (en) * 2007-08-14 2009-02-19 Bayer Schering Pharma Aktiengesellschaft Fused imidazoles for cancer treatment
EP2235019A1 (en) 2007-12-21 2010-10-06 Wyeth LLC Imidazo [1,2-b] pyridazine compounds as modulators of liver x receptors
US8536193B2 (en) 2008-06-03 2013-09-17 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
US8207169B2 (en) 2008-06-03 2012-06-26 Msd K.K. Substituted [1,2,4]triazolo[4′,3′:1,6]pyrido[2,3-b]pyrazines of the formula D
AR074072A1 (es) 2008-11-11 2010-12-22 Lilly Co Eli Compuesto de imidazol -piperidin -pirrol-pirimidin-6-ona, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar el glioblastoma multiforme
PA8854101A1 (es) 2008-12-18 2010-07-27 Ortho Mcneil Janssen Pharm Derivados de imidazol bicíclicos sustituidos como moduladores de gamma secretasa
CA2750051A1 (en) 2009-02-02 2010-08-05 Merck Sharp & Dohme Corp. Inhibitors of akt activity
MX2011008583A (es) * 2009-02-13 2011-12-12 Bayer Pharma AG Pirimidinas fusionadas.
WO2010104933A1 (en) 2009-03-11 2010-09-16 Merck Sharp & Dohme Corp. Inhibitors of akt activity
EP2413932A4 (en) * 2009-04-01 2012-09-19 Merck Sharp & Dohme HAMMER OF ACT ACTIVITY
AR076936A1 (es) 2009-06-02 2011-07-20 Vitae Pharmaceuticals Inc Inhibidores de carbamato y urea de la 11 beta hidroxiesteroide deshidrogenasa 1
WO2011033265A1 (en) * 2009-09-18 2011-03-24 Almac Discovery Limited Pharmaceutical compounds
JP5830094B2 (ja) * 2010-07-12 2015-12-09 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 置換イミダゾ［１，２−ａ］ピリミジンおよび−ピリジン
CA2806655A1 (en) 2010-07-28 2012-02-02 Bayer Intellectual Property Gmbh Substituted imidazo[1,2-b]pyridazines
SI2694510T1 (sl) * 2011-04-07 2016-02-29 Bayer Intellectual Property Gmbh Imidazopiridazini kot inhibitorji AKT kinaze

Also Published As

Publication number Publication date
HRP20160011T1 (hr) 2016-02-12
SG193631A1 (en) 2013-11-29
DK2694510T3 (en) 2016-01-18
WO2012136776A1 (en) 2012-10-11
BR112013025777A2 (pt) 2016-12-20
TN2013000400A1 (en) 2015-03-30
NZ616270A (en) 2015-09-25
ES2558780T3 (es) 2016-02-08
KR20140022057A (ko) 2014-02-21
US20140113901A1 (en) 2014-04-24
PL2694510T3 (pl) 2016-03-31
JO3068B1 (ar) 2017-03-15
CN103596957B (zh) 2016-12-07
RS54480B1 (sr) 2016-06-30
JP5906303B2 (ja) 2016-04-20
AU2012238589B2 (en) 2017-02-16
SMT201600001B (it) 2016-02-25
EA024890B1 (ru) 2016-10-31
DOP2013000226A (es) 2013-11-15
MX2013011699A (es) 2014-01-31
MA35016B1 (fr) 2014-04-03
ZA201307223B (en) 2014-12-23
US9206185B2 (en) 2015-12-08
EP2694510A1 (en) 2014-02-12
SI2694510T1 (sl) 2016-02-29
PE20141380A1 (es) 2014-10-18
ECSP13013008A (es) 2013-12-31
AR087148A1 (es) 2014-02-26
UA111739C2 (uk) 2016-06-10
PT2694510E (pt) 2016-02-08
MX336865B (es) 2016-02-04
US9604989B2 (en) 2017-03-28
NI201300105A (es) 2014-07-14
HUE026323T2 (en) 2016-05-30
GT201300238A (es) 2015-04-06
EP2694510B1 (en) 2015-10-14
UY34006A (es) 2012-10-31
IL228567A0 (en) 2013-12-31
AP2013007215A0 (en) 2013-10-31
TW201245204A (en) 2012-11-16
CL2013002878A1 (es) 2014-05-02
US20150368250A1 (en) 2015-12-24
CY1117163T1 (el) 2017-04-05
ME02316B (me) 2016-06-20
PH12013502073A1 (en) 2014-01-13
TWI535719B (zh) 2016-06-01
JP2014510127A (ja) 2014-04-24
CA2832374A1 (en) 2012-10-11
AP3597A (en) 2016-02-19
CN103596957A (zh) 2014-02-19
CU20130135A7 (es) 2014-02-28
CR20130515A (es) 2013-12-04
AU2012238589A1 (en) 2013-11-07
EA201301130A1 (ru) 2014-07-30
CO6862145A2 (es) 2014-02-10

Similar Documents

Publication Publication Date Title
CU24263B1 (es) Derivados de imidazopiridazinas inhibidores de quinasa akt, útiles para el tratamiento del cáncer
CR20140161A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
DOP2015000157A (es) Lactamas fusionadas de arilo y heteroarilo
PH12017502141A1 (en) Compounds and their methods of use
UY34960A (es) Dihidropiridona p1 como inhibidores del factor xia
CO6771439A2 (es) Inhibidores de benzodioxano de la producción de leucotrieno
UY35975A (es) Macrociclos con grupos p2? heterocíclicos como inhibidores del factor xia
EA201792205A1 (ru) Гетероциклические соединения как ингибиторы lsd1
MX2017003695A (es) Pirimidinonas como inhibidores del factor xia.
NI201600144A (es) Derivados de quinoxalina utiles como moduladores del fgfr cinasa
UY34959A (es) Dihidropiridona p1 como inhibidores del factor xia
CU24408B1 (es) Compuestos de dihidroisoquinolinona sustituida
GT201400178A (es) Compuestos de oxazolidin-2-ona y usos de los mismos como inhibidores de la pi3ks
MX378194B (es) Compuestos organicos.
TR201816379T4 (tr) DNA-PK inhibitörleri.
UY34955A (es) 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos
UA111075C2 (uk) Триазолопіридинові сполуки як інгібітори кінази рім
CU20140072A7 (es) Derivados de dihidro-oxazina y dihidro-pirido-oxazina
EA201590561A1 (ru) Пролекарства аминохиназолинового ингибитора киназы
EA201590552A1 (ru) Аминохинолины в качестве ингибиторов киназы
NZ711192A (en) Process for making benzoxazepin compounds
MX349548B (es) Compuestos de tienopirimidina.
DOP2015000176A (es) Compuestos de azetidiniloxifenilpirrolidina
EA201491227A1 (ru) Новые производные морфолинила, подходящие для применения в качестве ингибиторов mogat-2
EA201590656A1 (ru) Азаиндолины